Wednesday, June 7, 2017
- 1:15pm-2:45pm
-
Longitudinal analysis of the relation of dopamine agonist use with impulse control disorders in Parkinson’s disease
Parkinson's Disease: Psychiatric Manifestations · Exhibit Hall C
- 1:15pm-2:45pm
-
Longitudinal AV-1451 PET imaging in Progressive Supranuclear Palsy and Cortico-Basal Syndrome
Neuroimaging (Non-PD) · Exhibit Hall C
- 1:15pm-2:45pm
-
Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations
Neuroimaging (Non-PD) · Exhibit Hall C
- 1:15pm-2:45pm
-
MANF protects dopamine neurons and locomotion defect from Neurotoxin/Human alpha-synuclein-induced progressive Parkinson’s disease models in C.elegans.
Neuropharmacology · Exhibit Hall C
- 1:15pm-2:45pm
-
Mechanisms of sub-anesthetic ketamine infusions to reduce L-DOPA-induced dyskinesia: effects on striatal mTOR signaling and beta band oscillations in striatum and motor cortex
Neuropharmacology · Exhibit Hall C
- 1:15pm-2:45pm
-
Medication optimization in Parkinson’s disease patients with ON-state freezing using objective gait assessments
Phenomenology and Clinical Assessment Of Movement Disorders · Exhibit Hall C
- 1:15pm-2:45pm
-
Meta-analysis of the interaction between HLA-DRB1 and smoking with Parkinson’s disease
Parkinson's Disease: Genetics · Exhibit Hall C
- 1:15pm-2:45pm
-
Metabolic pattern of acute hemichorea associated with contralateral carotid stenosis
Choreas (Non-Huntington’s Disease) · Exhibit Hall C
- 1:15pm-2:45pm
-
Middle cerebellar peduncle width in multiple system atrophy
Neuroimaging (Non-PD) · Exhibit Hall C
- 1:15pm-2:45pm
-
Mild cognitive impairment in newly diagnosed Parkinson’s disease: a three year follow up
Parkinson's Disease: Cognition · Exhibit Hall C
- «Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 38
- Next Page»